S6 Ep42: Jabbour Highlights New Data With Asciminib and Ponatinib in CML
OncLive® On Air
00:00
Long-Term Experience with Ponatinib
Elias Jabbour discusses a decade of ponatinib use, its potency, and dose-reduction practices to manage vascular risk.
Play episode from 07:56
Transcript
